Float Short %

11.93

Margin Of Safety %

Put/Call OI Ratio

0.22

EPS Next Q Diff

0.01

EPS Last/This Y

EPS This/Next Y

0.03

Price

50.26

Target Price

79.75

Analyst Recom

1.32

Performance Q

-3.23

Relative Volume

1.55

Beta

0.94

Ticker: CYTK

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	CYTK	47.76	0.27	0.08	28581
2025-01-24	CYTK	50.72	0.27	0.13	29573
2025-01-27	CYTK	50.29	0.26	0.13	30779
2025-01-28	CYTK	48.74	0.25	0.54	31327
2025-01-29	CYTK	48.61	0.25	0.03	31632
2025-01-30	CYTK	50	0.25	0.01	31982
2025-01-31	CYTK	49.68	0.24	0.14	32209
2025-02-03	CYTK	48.45	0.24	0.78	32844
2025-02-04	CYTK	49.18	0.24	0.42	32841
2025-02-05	CYTK	50.42	0.24	0.02	33316
2025-02-06	CYTK	46.22	0.23	0.13	33936
2025-02-07	CYTK	42.73	0.23	0.25	36304
2025-02-10	CYTK	42.24	0.23	0.17	38290
2025-02-11	CYTK	41.58	0.22	0.49	40578
2025-02-12	CYTK	42.16	0.23	0.83	41729
2025-02-13	CYTK	41.6	0.23	0.20	42146
2025-02-14	CYTK	46.17	0.23	0.25	42738
2025-02-18	CYTK	45.42	0.24	0.21	48579
2025-02-19	CYTK	46.44	0.25	0.41	49740
2025-02-20	CYTK	51.08	0.25	0.04	49979
2025-02-21	CYTK	50.26	0.22	0.18	55089
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	CYTK	47.86	13.1	-152.7	-5.20
2025-01-24	CYTK	50.74	13.1	-177.7	-5.20
2025-01-27	CYTK	50.00	11.3	-128.4	-5.20
2025-01-28	CYTK	48.73	11.3	-122.1	-5.20
2025-01-29	CYTK	48.60	11.3	-136.7	-5.20
2025-01-30	CYTK	49.97	11.3	-156.0	-5.20
2025-01-31	CYTK	49.63	11.3	-133.6	-5.20
2025-02-03	CYTK	48.47	11.3	-124.8	-5.20
2025-02-04	CYTK	49.18	11.3	-147.8	-5.20
2025-02-05	CYTK	50.37	11.3	-154.0	-5.20
2025-02-06	CYTK	46.20	11.3	-83.2	-5.20
2025-02-07	CYTK	42.73	11.3	-88.8	-5.20
2025-02-10	CYTK	42.21	11.3	-129.6	-5.20
2025-02-11	CYTK	41.57	11.3	-128.0	-5.20
2025-02-12	CYTK	42.17	11.3	-147.8	-5.20
2025-02-13	CYTK	41.59	11.3	-128.7	-5.20
2025-02-14	CYTK	46.16	11.3	-210.4	-5.20
2025-02-18	CYTK	45.42	14.9	-127.5	-5.20
2025-02-19	CYTK	46.40	14.9	-152.8	-5.20
2025-02-20	CYTK	51.12	14.9	-205.3	-5.20
2025-02-21	CYTK	50.26	14.9	-127.0	-5.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	CYTK	-3.66	0.37	12.07
2025-01-24	CYTK	-3.51	0.37	12.07
2025-01-27	CYTK	-3.51	0.07	12.07
2025-01-28	CYTK	-3.51	0.07	12.36
2025-01-29	CYTK	-3.51	0.07	12.36
2025-01-30	CYTK	-3.51	0.07	12.36
2025-01-31	CYTK	-3.51	0.07	12.36
2025-02-03	CYTK	-3.16	-0.02	12.36
2025-02-04	CYTK	-3.21	-0.02	12.36
2025-02-05	CYTK	-3.21	-0.02	12.36
2025-02-06	CYTK	-3.21	-0.02	12.36
2025-02-07	CYTK	-3.21	-0.02	12.36
2025-02-10	CYTK	-3.05	0.18	12.36
2025-02-11	CYTK	-3.04	0.18	12.36
2025-02-12	CYTK	-3.04	0.18	12.02
2025-02-13	CYTK	-2.70	0.18	12.02
2025-02-14	CYTK	-2.70	0.18	12.02
2025-02-18	CYTK	-2.70	-0.09	12.02
2025-02-19	CYTK	-2.18	-0.09	12.15
2025-02-20	CYTK	-3.45	-0.09	11.93
2025-02-21	CYTK	-3.45	-0.09	11.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.36

Avg. EPS Est. Current Quarter

-1.22

Avg. EPS Est. Next Quarter

-1.35

Insider Transactions

-3.45

Institutional Transactions

-0.09

Beta

0.94

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

54.4

Max Drawdown 5-Year %

-61.5

Target Price

79.75

P/E

Forward P/E

PEG

P/S

1842.05

P/B

P/Free Cash Flow

EPS

-5.39

Average EPS Est. Cur. Y

-5.2

EPS Next Y. (Est.)

-5.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-17906.24

Relative Volume

1.55

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.12

EBIT Estimation

-127

Cytokinetics, Incorporated

Sector: Healthcare

Industry: Biotechnology

Employees: 423

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today

news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance

stock history CYTK – Cytokinetics, Incorporated invest stock market

stock prices CYTK premarket after hours

ticker CYTK fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CYTK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y